Combined pulmonary and thoracic wall resection for stage III lung cancer

Samir S Shah, Peter Goldstraw

Abstract

Background — Carcinoma of the lung with thoracic wall involvement constitutes stage III disease. The management of patients with this condition is complicated. However, improvement in perioperative care coupled with advances in surgical technique have enabled a more aggressive approach to the problem to be adopted.

Methods — A retrospective review was carried out on 58 patients (40 men) of mean age 63 years who underwent thoracotomy for lung cancer with chest wall invasion between 1980 and 1993.

Results — Chest wall resection was performed in 55 patients (94·8%); in three patients the discovery of N2 disease at operation precluded resection. The TNM status was T3N0M0 in 38 patients, T3N1M0 in 13, and T3N2M0 in seven. Squamous cell carcinoma was the commonest cell type (26 patients). Reconstruction of the chest wall was performed in 29 patients (Marlex mesh in six, Marlex-methacrylate in 22, myocutaneous flap in one patient). The morbidity and mortality were 22·4% and 3·4% respectively. Follow up was complete in 51 patients. Nineteen (37·2%) survived ≥5 years. The absolute five year survival for N0 and N1 disease was 44·7% and 38·4%, respectively. No patients with N2 disease survived five years.

Conclusions — In patients with carcinoma of the lung and chest wall invasion, combined pulmonary and thoracic wall resection offers the prospect of cure with minimal morbidity and mortality. The prognosis of patients with coexistent N2 disease remains poor.

(Thorax 1995;50:782–784)

Keywords: lung cancer, thoracotomy.

Direct chest wall invasion occurs in 2–8% of patients with carcinoma of the lung.1,2 It is important to identify this group of patients as they constitute a subgroup of stage III disease in whom the prospect of surgical resection and cure is favourable. The present study reviews the results of surgical intervention in all patients with carcinoma of the lung and chest wall invasion seen between 1980 and 1993 at the Royal Brompton Hospital.

Methods

A retrospective review of all patients who underwent combined pulmonary and thoracic wall resection between 1980 and 1993 was carried out. The patients were subject to a uniform preoperative staging protocol as described previously.3 After history taking and physical examination each patient underwent routine blood tests (full blood count, serum electrolytes and liver function tests), chest radiography, and a computed tomographic (CT) scan of the brain, chest, and abdomen.

An isotopic bone scan to rule out distant metastases was performed in any patient with unexplained weight loss, anaemia, bone pain, abnormalities in serum calcium or alkaline phosphatase, or a combination of these signs and symptoms. Any discrepancy on the bone scan was further evaluated by skeletal radiographs.

Rigid bronchoscopy was routine in all patients. In addition, cervical mediastinoscopy (supplemented by left anterior mediastinotomy if the tumour was located in the left upper lobe or extended to the left main bronchus) was undertaken in any patient in whom the CT scan of the mediastinum suggested invasion or lymphadenopathy. No patient with a positive mediastinoscopy proceeded to thoracotomy.

The staging process continued at thoracotomy in the form of mediastinal nodal dissection of all nodes including those of normal size and consistency. Frozen section examination of nodes was carried out when indicated.

Results

Fifty eight patients (40 men) aged 39–87 years (median 59, mean 63) without evidence of distal metastases or medical contraindication came to thoracotomy. Nineteen (32·8%) underwent mediastinoscopy prior to thoracotomy. The histological cell type and TNM classification (according to the International Staging System for Lung Cancer4) are shown in table 1.

Resection was undertaken in 55 patients (94·8%). Three (5·2%) had extensive nodal involvement.

Table 1: Histological cell type and TNM status

<table>
<thead>
<tr>
<th>Histological cell type</th>
<th>No. of patients (N=58)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Squamous cell carcinoma</td>
<td>26</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>17</td>
</tr>
<tr>
<td>Pancoast's tumour</td>
<td>6</td>
</tr>
<tr>
<td>Large cell carcinoma</td>
<td>5</td>
</tr>
<tr>
<td>Small cell carcinoma</td>
<td>2</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>2</td>
</tr>
<tr>
<td>pT3N0M0</td>
<td>38</td>
</tr>
<tr>
<td>pT3N1M0</td>
<td>13</td>
</tr>
<tr>
<td>pT3N2M0</td>
<td>7</td>
</tr>
</tbody>
</table>

* Includes three patients in whom resection was precluded by the presence of mediastinal lymph node involvement (N2 disease).

No. of patients (N=58)*

Squamous cell carcinoma 26
Adenocarcinoma 17
Pancoast's tumour 6
Large cell carcinoma 5
Small cell carcinoma 2
Adenocarcinoma 2
pT3N0M0 38
pT3N1M0 13
pT3N2M0 7*
involvement (N2 disease) at thoracotomy and were deemed inoperable. In all three patients the preoperative CT scan of the chest was equivocal and mediastinoscopy had been negative. The extent of chest wall resection and type of pulmonary resection performed are shown in tables 2 and 3.

The residual defect required reconstruction in 29 patients (50%). Marlex mesh was used in six patients and a composite of Marlex and methylmethacrylate in 22 patients. In one patient the Marlex-methylmethacrylate “sandwich” was used in conjunction with a myocutaneous flap (utilising the latissimus dorsi muscle).

There were no operative deaths. The hospital mortality was 3·4% (two patients). The cause of death was progressive respiratory failure in one case and multisystem failure in the second. The morbidity, as defined by a new postoperative complication or clinical/microbiological evidence of infection, was 22·4% (13 patients) – wound infection in six patients, chest infection in five, persistent air leak in one, and atrial fibrillation in one patient.

The period of follow up ranged from 0 to 104 months and was complete in 51 patients (87·9%). Seven patients were lost to follow up and were omitted from further analysis. In 32 patients recurrent carcinoma was proved or strongly suspected at the time of death, three patients died of unrelated causes, and 16 patients were alive at the time of follow up. None of the late deaths was attributable to the operation. Overall, 19 patients (37·2%) survived ≥5 years. Absolute five year survival with respect to the node status of the patient was 44·7% (17 patients) and 38·4% (five patients) for N0 and N1 disease, respectively. No patient with N2 disease survived five years.

Discussion

The high mortality and morbidity encountered by surgeons operating on patients with lung cancer invading the chest wall was largely responsible for the pessimistic prognosis ascribed to these patients in the past. The advent of mechanical ventilation and the marked improvement in the perioperative management of the patients did much to revive interest in the role of surgery in the treatment of this condition. Coleman was the first of many investigators to report favourable outcome and long term survival following combined chest wall and pulmonary resection for carcinoma of the lung.

The identification of patients with carcinoma of the lung and chest wall involvement, in whom surgical intervention offers the prospects of cure, has been recognised by the new International Staging System for Lung Cancer which divides stage III disease into IIIA and IIIB on the basis of complete resectability. The operative management of a patient with this condition remains complicated. The need to achieve satisfactory margins of clearance often results in a defect that leaves intrathoracic structures exposed, requires immobilisation to allow adequate chest wall excision during respiration, and presents a constant risk of bacterial contamination. Furthermore, in all but the most limited resection, or where the resected segment lies entirely beneath the pectoral girdle, some degree of reconstruction is mandatory to prevent respiratory compromise.

The technical aspect of the operation has been aided by two advances. Firstly, the development of prosthetic materials has enabled the structural integrity of the chest wall to be re-established. Although various materials (ranging from stainless steel plates to dura mater) have been utilised previously, these have now been superseded by flexible meshes of different thicknesses and grades. Our preferred choice is Marlex mesh, a single stitch fabric that is rigid in one direction and stretchable in the opposite direction. The mesh, when sutured to the surrounding skeletal margin, provides a semirigid prosthesis that allows the ingrowth of tissue, thus enabling it to become incorporated into the chest wall. Added rigidity, when dealing with a large defect or the contour of the lateral chest wall, can be obtained by using the mesh in combination with methylmethacrylate as described by McCormack et al. The second advance has come with the clarification and understanding of the functional anatomy and blood supply of the thoracoabdominal musculature coupled with improvements in microvascular surgical techniques. This has allowed even complex wounds to be managed successfully using a variety of myocutaneous flaps.

The present study highlights several factors that are important to consider in the management of patients with carcinoma of the lung and chest wall invasion. Firstly, the value of accurate preoperative staging cannot be overemphasised. We consider mediastinal exploration mandatory in patients in whom the CT scan of the chest suggests invasion or lymphadenopathy. Mediastinoscopy and left anterior mediastinotomy are associated with minimal complications in experienced hands and have a sensitivity of 91% and specificity of 100%. The need to exclude N2 disease is
crucial not just in terms of the possibility of resection but also its desirability. Several studies have demonstrated that the presence of N2 disease carries a poor prognosis.\textsuperscript{14,24,25} In the present series no patient with N2 disease survived five years. Careful staging also avoids unnecessary operations. Of the 58 patients who came to thoracotomy, 94.8\% went on to have a resection performed—a figure that is comparable to our experience with both non-small cell and small cell carcinoma of the lung without chest wall involvement.\textsuperscript{26,27}

The morbidity and mortality in this series were 22.4\% (13 patients) and 3.4\% (two patients) respectively, which compare favourably with other series.\textsuperscript{24,25,28,29} Wound infection (six patients) was the most common postoperative problem and in each case this was treated successfully with simple wound toilet and dressing changes. Of the five patients who developed a postoperative chest infection a mirtitracheostomy for sputum retention was inserted in one patient and one required intermittent positive pressure ventilation. The latter died of progressive respiratory failure. The second death occurred in a patient who had a stormy postoperative course and died of multisystem failure. The absence of major complications and the low mortality rate is a reflection both of rigorous preoperative assessment and of the important advances that have been made in the postoperative care of patients. It stresses the need for a multidisciplinary approach to the management of these patients involving a team of anaesthetists/intensivists, physiotherapists and nursing staff fully conversant with the condition and the procedure. In addition, plastic surgeons are routinely involved in the preoperative planning whenever an extensive resection is being contemplated, although to date only one patient has required a myocutanous flap.

None of the operations in our series was undertaken purely for palliation. The reasons for this are threefold: firstly, the success of the operation in terms of achieving symptom control, such as relief of chest wall pain, has been variable; secondly, the prognosis for a patient in whom a complete resection has not been possible is generally poor; and thirdly, the operation itself is a major procedure carrying with it not insignificant morbidity.\textsuperscript{2,21,28}

The role of adjuvant therapy in these patients remains unclear. Most attention has centred on the role of radiotherapy, and although Patterson \textit{et al} reported an improved survival and lower local recurrence rate in patients who received radiation, the results were not significant. Other studies have found no difference in long term survival with the use of postoperative radiotherapy.\textsuperscript{13,24,25} Clearly adjuvant therapy, both in terms of radiotherapy and chemotherapy, in patients with these tumours merits further evaluation. As far as the present series is concerned, we have no uniform policy with respect to adjuvant therapy largely due to the fact that, being a tertiary referral centre, the patients referred to us are under the care of colleagues with differing opinions on the subject.

In conclusion, we believe that combined pulmonary and thoracic wall resection offers the prospects of cure in a important subgroup of patients with stage III lung cancer if N2 nodes are not involved. Furthermore, with careful preoperative assessment and a multidisciplinary approach to postoperative care this can be achieved with minimal morbidity and mortality.


10 Hedblom CA. Tumors of the bony chest wall. \textit{Arch Surg} 1921;5:36-85.


13 Coleman FP. Primary carcinoma of the lung with invasion of the ribs. Pneumonectomy and simultaneous block resection of the chest wall. \textit{Ann Surg} 1947;126:156-68.


Combined pulmonary and thoracic wall resection for stage III lung cancer.

S S Shah and P Goldstraw

Thorax 1995 50: 782-784
doi: 10.1136/thx.50.7.782

Updated information and services can be found at:
http://thorax.bmj.com/content/50/7/782

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/